company

AbbVie

ABBVAbbVie (prior sponsor, Abbott)
CIK 0001551152ticker ABBV
as of 2026-07-01
Monitor thisAsk about this
at a glance
Cash $9.4B (as of 2026-03-31)
Revenue $15.0B
13 trials sponsored · 6 assets in the graph
Synthesized from structured facts only — each point cited above.

Financials

SEC EDGAR XBRL · latest period per metric
Cash$9.4B2026-03-31
Ga Expense$3.6B2026-03-31
Net Income Loss$695.0M2026-03-31
Revenue$15.0B2026-03-31
Rnd Expense$2.5B2026-03-31
Stockholders Equity-$6.7B2026-03-31
Total Assets$136.5B2026-03-31

Pipeline

6 assets
Cariprazine (Vraylar)EmraclidineABT-126ABT-288ABT-288 High DoseABT-288 Low Dose

Recent filings

SEC EDGAR
11-Kopen ↗2026-06-24
8-Kopen ↗2026-06-22
SDopen ↗2026-06-01
144open ↗2026-05-26
4open ↗2026-05-12
4open ↗2026-05-12
4open ↗2026-05-12
4open ↗2026-05-12
8-Kopen ↗2026-05-12
4open ↗2026-05-12
4open ↗2026-05-12
4open ↗2026-05-12

Facts & assertions

8 sourced
Financial Status
profitable
Latest Cash
9,391,000,000
Latest Ga Expense
3,578,000,000
Latest Net Income Loss
695,000,000
Latest Revenue
15,002,000,000
Latest Rnd Expense
2,472,000,000
Latest Stockholders Equity
-6,656,000,000
Latest Total Assets
136,463,000,000
relationships
The graph out of here
asset
Cariprazine (Vraylar)
small molecule
drug
Emraclidine
small molecule
drug
ABT-126
small molecule
drug
ABT-288
small molecule
drug
ABT-288 High Dose
small molecule
drug
ABT-288 Low Dose
small molecule
drug